Jennifer Litton, associate professor of breast Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the results of the EMBRACA study she presented at the 2017 San Antonio Breast Cancer Symposium showing that talazoparib, an experimental targeted therapy medicine, improved the time until the cancer grew in women with a BRCA1 or BRCA2 mutation who had been diagnosed with metastatic HER2-negative breast cancer compared to chemotherapy. Listen to the podcast to hear Dr. Litton explain: how talazoparib works whether talazoparib will offer benefits to women with other mutations linked to a higher risk of breast cancer how the side effects differed between talazoparib and chemotherapy why quality of life was better in women who were treated with talazoparib Editor's Note: Talzenna (chemical name: talazoparib) was approved by the U.S. Food and Drug Administration on Oct. 16, 2018, for the treatment of metastatic breast cancer in women with BRCA mutations. Learn more about Talzenna.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related